Table 1 Correlations between CA9 expression and clinicopathological parameters in CNB of 102 primary breast cancers
| Â | Â | CA9 expression | Â |
|---|---|---|---|
Parameter | Positive | Negative | Â |
|  | (n = 47) | (n = 55) | p-value |
Age | Â | Â | Â |
≥55 | 21 (42%) | 29 (58%) |  |
<55 | 26 (50%) | 26 (50%) | 0.418 |
Menopause | Â | Â | Â |
Positive | 31 (44%) | 40 (56%) | Â |
Negative | 16 (52%) | 15 (48%) | 0.459 |
Intrinsic subtype | Â | Â | Â |
Luminal | 22 (48%) | 24 (52%) | Â |
Luminal-HER | 4 (50%) | 4 (50%) | Â |
HER2 | 4 (24%) | 13 (76%) | 0.209 |
Triple-negative | 17 (55%) | 14 (45%) | Â |
Tumor size | Â | Â | Â |
≥ 4 cm | 12 (67%) | 6 (33%) |  |
< 4Â cm | 35 (42%) | 49 (58%) | 0.053 |
Lymph node status | Â | Â | Â |
Positive | 23 (70%) | 10 (30%) | Â |
Negative | 24 (35%) | 45 (65%) | 0.001 |
Lymph-vascular invasion | Â | Â | Â |
Positive | 20 (69%) | 9 (31%) | Â |
Negative | 27 (37%) | 46 (63%) | 0.003 |
Nuclear grade (NG) | Â | Â | Â |
NG1 | 32 (43%) | 42 (57%) | Â |
NG 2&3 | 15 (54%) | 13 (46%) | 0.350 |
Pathological response | Â | Â | Â |
pCR | 7 (23%) | 23 (77%) | Â |
Non-pCR | 40 (56%) | 32 (44%) | 0.003 |
Responder (histological grade 2&3) | 16 (29%) | 40 (71%) | Â |
non-Responder (histological grade 1) | 31 (67%) | 15 (33%) | <0.001 |
Clinical response | Â | Â | Â |
Responder (cCR + cPR) | 33 (41%) | 47 (59%) |  |
non-Responder (cNC + cPD) | 14 (64%) | 8 (36%) | 0.062 |
Recurrence | Â | Â | Â |
Yes | 22 (79%) | 6 (21%) | Â |
No | 25 (34%) | 49 (66%) | <0.001 |